Onyx Pharmaceuticals is finally sold – the happy buyer is Amgen. The deal is worth $10.4 bln and it gives Amgen access to a rapidly expanding cancer market with a new promising drug. I think it’s good for Amgen. In longer term it’ll give the company needed stability of revenue and fill a hole in its product line, and $10 bln isn’t such a huge sum to pay for such self-improvement.